Delaware Health News Online
SEE OTHER BRANDS

The latest health and wellness news from Delaware

Delaware Health News Online: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Delaware Health News Online.

Press releases published on August 4, 2025

OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference

OrthoPediatrics Corp. to Participate in the 45th Canaccord Genuity Annual Growth Conference

WARSAW, Ind., Aug. 04, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President …

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

RADNOR, Pa., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as hypertensive nephropathy, …

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

iMDx to Release Second Quarter 2025 Results on August 11, 2025 and Attend Needham Virtual MedTech and Diagnostics Conference

NASHVILLE, Tenn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will report second quarter 2025 financial results after the market closes on Monday, August 11, 2025. iMDx will host a live …

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and …

FibroGen to Report Second Quarter 2025 Financial Results

FibroGen to Report Second Quarter 2025 Financial Results

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern …

Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with …

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Ardelyx Reports Second Quarter 2025 Financial Results and Provides Business Update

Company reports strong commercial performance in the second quarter, recording $97.7 million in total revenue, reflecting 33% growth year-over-year IBSRELA generated net sales revenue of $65.0 million; XPHOZAH generated net sales revenue of $25.0 million …

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug …

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – – $36.2 million of Niktimvo™ (axatilimab-csfr) net revenue reported by Incyte in first full quarter of launch; $9.4 million in collaboration revenue reported by …

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage …

Dunham House to Partner with CrossMed Healthcare Staffing

Dunham House to Partner with CrossMed Healthcare Staffing

OMAHA, Neb., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dunham House, a first-of-its-kind, transformational initiative for combat-wounded veterans in need of long-term residential-centered care for their wounds, will partner with Omaha-based CrossMed Healthcare …

ACGME International Expands to Indonesia, Accredits New Programs in Japan and Lebanon

ACGME International Expands to Indonesia, Accredits New Programs in Japan and Lebanon

Chicago, Illinois, US, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ACGME International (ACGME-I) is proud to announce the beginning of its accreditation activities in Indonesia as six institutions have achieved Initial Accreditation. The newly accredited Sponsoring …

Media advisory: Shriners Hospitals for Children Canada Invites Media to its Annual Golf Tournament

Media advisory: Shriners Hospitals for Children Canada Invites Media to its Annual Golf Tournament

MONTREAL, Aug. 04, 2025 (GLOBE NEWSWIRE) -- What:     Shriners Hospitals for Children Canada invites members of the media to attend a special photo and interview opportunity during its Annual Golf Tournament at Summerlea Golf …

Avis aux médias: L’Hôpital Shriners pour enfants Canada invite les médias à son tournoi de golf annuel

Avis aux médias: L’Hôpital Shriners pour enfants Canada invite les médias à son tournoi de golf annuel

Quoi :   L’Hôpital Shriners pour enfants Canada convie les représentants des médias à une occasion spéciale de photos et d’entrevues dans le cadre de son tournoi de golf annuel, qui se tiendra au club Summerlea Golf …

PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007

PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007

PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm. A parallel study presented to …

Healthcare Workforce Management Market Surges Amid Drive for Operational Efficiency and Cost Reduction

Healthcare Workforce Management Market Surges Amid Drive for Operational Efficiency and Cost Reduction

Boston, Aug. 04, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, the “Global Healthcare Workforce Management System Market” is expected to grow from $1.9 billion in 2024 to $3.1 billion by the end of 2029, at a compound annual …

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025

Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the …

Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight

Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight

New York, USA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight  The neuroendocrine prostate cancer treatment space will experience …

L’Avenue Derm: The Blueprint for Seven-Day Dermatologic Care, Revolutionizing Skin Health and Aesthetics

L’Avenue Derm: The Blueprint for Seven-Day Dermatologic Care, Revolutionizing Skin Health and Aesthetics

L’Avenue Derm debuts in Manhattan with a one-month waitlist, redefining holistic dermatologic care. Members receive 7-day access to top dermatologists, yoga, nutrition, and tailored aesthetic treatments—seamlessly blending convenience and clinical …

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes

Data Demonstrate that Sana’s Hypoimmune (HIP)-Modified Pancreatic Islet Cells, Transplanted with No Immunosuppression, Persist and Function Over Time in Patient with Type 1 Diabetes Study Establishes Ability to Genetically Modify and Transplant Pancreatic …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions